This webinar was developed and funded by Almirall and is intended for healthcare professionals only. The speakers received honoraria for their participation.
Lebrikizumab▼ is approved by the EMA and MHRA and authorised for commercialisation in a number of markets including Germany, Spain and UK. Prescribing Information for lebrikizumab for the UK can be found here. The European Summary of Product Characteristics can be found here.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
All Adverse Events must be reported using the reporting framework of your local supervisory authority. UK adverse events reporting can be found at the end of this landing page.
Listen to experts Stephan Weidinger and Christian Vestergaard discuss rapid and sustained disease control in moderate-to-severe atopic dermatitis, including the challenging face and neck areas, with a focus on lebrikizumab. They examine where lebrikizumab fits within current European treatment guidelines and how onset of action, response, and long-term disease control may address key unmet needs in clinical practice.
Key Topics:
- Advances in biologic therapy for moderate-to-severe atopic dermatitis
- Early onset, durable response, and long-term disease control
- Patient-centred outcomes and long-term safety considerations
Speakers
Stephan Weidinger1,2
Christian Vestergaard3
1. Christian-Albrechts-University, Kiel, Germany
2.University Hospital Schleswig-Holstein, Kiel, Germany
3. Aarhus University Hospital, Denmark
| For UK citizens: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
For non-UK citizens: If you need to report an Adverse Event, Product Quality Complaint or require Medical Information please call Almirall on 0800 0087399 or email [email protected]. |
